However, a recent large-scale RCT reported an increased risk of MACEs with tofacitinib compared to that with a tumor necrosis factor (TNF) inhibitor in patients aged ≥50 years with RA and CV risk factors (Ytterberg et al., 2022). The gene discussed is TNF; the disease is rheumatoid arthritis.